Results 71 to 80 of about 14,868 (228)
Development of an 123I-metaiodobenzylguanidine Myocardial Three-Dimensional Quantification Method for the Diagnosis of Lewy Body Disease [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2018 Objective(s): We recently developed a new uptake index method for123I-metaiodobenzylguanidine (123I-MIBG) heart uptake measurements by using planarimages (radioisotope angiography and planar image) for the diagnosis of Lewy bodydisease (LBD), including ...
Yoshito Kamiya +5 more
doaj +1 more source
Reduced Dopamine Transporter Uptake in Dentatorubral‐Pallidoluysian Atrophy
Movement Disorders Clinical Practice, EarlyView.
Kei Okuba +3 more
wiley +1 more source
Regressive Neuroblastoma: Widely Accepted, Underreported Histology
Clinical Case Reports, Volume 14, Issue 5, May 2026.Whole‐mount section of the regressed neuroblastoma within the adrenal gland, showing a loose, collagenous, and edematous stroma. ABSTRACT Neuroblastoma accounts for approximately 8% of all pediatric cancers and up to 15% of pediatric cancer‐related deaths in malignant cases; neuroblastoma is the most common malignancy in infancy.
Tom Membrez +5 more
wiley +1 more source
Бюллетень сибирской медицины, 2014 The aim of this study was assessment of cardiac sympathetic activity in patients with atrial fibrillation by planar scintigraphy with 123I-metaIodbenzilguanidine (123I-MIBG).Material and Methods.
Yu. B. Lishmanov +4 more
doaj +1 more source
Journal of Internal Medicine, Volume 299, Issue 5, Page 615-627, May 2026.Abstract Background Current guidelines recommend at least 10 years of follow‐up for all pheochromocytoma and paraganglioma (PPGL) patients and lifelong monitoring for high‐risk individuals. Nonetheless, data identifying patients who may not require routine lifelong follow‐up are scarce. Methods Among 999 patients with PPGL, 703 who were non‐metastatic,
Min Jeong Park +15 more
wiley +1 more source
New targeting agent for the selective drug delivery of nanocarriers for treating neuroblastoma [PDF]
, 2015 Novel targeting agents against neuroblastoma based on the meta-iodobenzylguanidine (MIBG) moiety were synthesized and biologically evaluated for nanocarrier vectorization. These compounds have been anchored on the surface of drug loaded mesoporous silica
Alfranca, Arantzazu +5 more
core +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.ABSTRACT Introduction Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis, but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available.
Vicente Santa‐Maria Lopez +13 more
wiley +1 more source
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]
, 2016 PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly +9 more
core +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell +14 more
wiley +1 more source
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION Quantitative evaluations of how recommendations influence clinical practice are limited. This study assessed changes in the diagnostic pathways after the 2020 Italian Intersocietal Consensus Recommendations (IICR) for biomarker‐based dementia diagnosis.
Cristina Festari +17 more
wiley +1 more source